DOI: https://doi.org/10.22141/2224-0713.8.94.2017.120703

Efficiency and expediency of using naproxen in various clinical situations

I.Yu. Golovach

Abstract


The review article presents evidence of the clinical efficacy of naproxen in the treatment of rheumatological patients. The modern concept of the rational and safe use of non-steroidal anti-inflammatory drugs (NSAIDs) involves achieving maximum efficiency together with the maximum reduction in the risk of complications, primarily from the cardiovascular and gastrointestinal systems. According to clinical studies, among all NSAIDs the lowest
risk of cardiovascular complications is noted for naproxen. Napro­xen belongs to the group of non-selective NSAIDs, has been actively used in clinical practice for more than 40 years and has won the trust of doctors as a reliable analgesic and anti-inflammatory drug. The therapeutic potential of naproxen has been proven in various clinical situations — from acute episodes of pain and inflammation and to the treatment of chronic pain syndrome in rheumatological practice. The article presents and analyzes randomized clinical trials that emphasize the clinical efficacy and safety of naproxen in acute gouty arthritis, acute injuries, osteoarthritis, rheumatoid arthritis and spondyloarthritis.


Keywords


non-steroidal anti-inflammatory drugs; chronic pain syndrome; safety; efficacy; naproxen

References


Головач І.Ю. Кардіоваскулярна безпека як важливий критерій вибору нестероїдних протизапальних препаратів // Міжнародний неврологічний журнал. — 2017. — № 6(92). — 68-74.

Довгань В.Е. Результаты исследования PRECISION: удалось ли ответить на вопрос, насколько безопасны коксибы в сравнении с «традиционными» нестероидными противовоспалительными препаратами у пациентов с высоким риском развития сердечно-сосудистых осложнений? // Современная ревматология. — 2017. — 11(3). — 129-131.

Каратеев А.Е. Напроксен: универсальный анальгетик с минимальным риском кардиоваскулярных ослонений // Современная ревматология. — 2016. — 2. — 70-77.

Муравьев Ю.В. Почему исследование комплексной

безопасности целекоксиба при артритах, названное РRECISION, является последним по счету, а не по значимости? // Научно-практическая ревматология. — 2017. — 55(3). — 324-326.

Олюнин Ю.А. Применение нестероидных противовоспалительных препаратов у больных с высоким кардиоваскулярным риском // Научно-практическая ревматология. — 2017. — 55(3). — 321-323.

Aeidler H. Clinical results of a multicentral double-blind examination of naproxen compared to indomethacin in chronic rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis // Arzneimittelforschung. — 1975. — 25(2A). — 315-318.

Blechman W., Willkens R., Boncaldo G. et al. Naproxen in osteoarthrosis. Double-blind crossover trial // Ann. Rheum. Dis. — 1978. — 37(1). — 80-84.

Bombardier C., Laine L., Reicin A., et al. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis // N. Engl. J. Med. — 2000. — 343(21). — 1520-1528.

Bruyere O., Cooper C., Pelletier J.P. et al. An algorithm re­commendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) // Semin. Arthritis Rheum. — 2014. — 44. — 253-263.

Bruyère O., Cooper C., Pelletier J.-P. et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis — From evidence-based medicine to the real-life setting // Semin. Arthritis Rheum. — 2016. — 45(4). — S3-S11.

Calligaris A., Scaricabarozzi I., Vecchiet L. A multicentre double-blind investigation comparing nimesulide and naproxen in the treatment of minor sport injuries // Drugs. — 1993. — 46(1). — 187-190.

Collantes E., Curtis S.P., Lee K.W. et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis // BMC Fam. Pract. — 2002. — 3. — 10.

Eyman E., Brzozowska-Jurkowska A.M., Werynska-Przybylska J., Kawenoki-Minc E. Effect of naproxen on gout attacks // Reumatologia. — 1980. — 18(1). — 1-4.

Farkouh M., Kirshner H., Harrington R. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial // Lancet. — 2004. — 364(9435). — 675-684.

Fathi M., Zare M.A., Bahmani H.R., Zehtabchi S. Comparison of oral oxycodone and naproxen in soft tissue injury pain control: a double-blind randomized clinical trial // Am. J. Emerg. Med. — 2015. — 33(9). — 1205-1208.

Fioravanti A., Storri L., Di Martino S. et al. A randomized, double-blind, multicenter trial of nimesulide-beta-cyclodextrin versus naproxen in patients with osteoarthritis // Clin. Тherapeutics. — 2002. — 24(4). — 504-519.

Gimenez M., Pujol J., Ali Z. et al. Naproxen effects on brain response to painful pressure stimulation in patients with knee osteoarthritis: a double-blind, randomized, placebo-controlled, single-dose study // J. Rheumatol. — 2014. — 41(11). — 2240-2248.

Janssens H.J., Janssen M., van de Lisdonk E.H. et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial // Lancet. — 2008. — 371(9627). — 1854-1860.

Kroon F.P., van der Burg L.R., Ramiro S. et al. Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review // J. Rheumatol. — 2016. — 43(3). — 607-617.

Latourte A., Bardin T., Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy // Rheumato­logy (Oxford). — 2014. — 53(11). — 1920-1926.

Mehmood Y., Riaz H., Yousaf H. Formulation and in vitro evaluation of colchicines and naproxen sodium sustain release tablets in combination for treatment of gout // Pak. J. Pharm. Sci. — 2016. — 29(5). — 1579-1586.

Moore R.A., Moore O.A., Derry S. et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice // Ann. Rheum. Dis. — 2010. — 69(2). — 374-379.

Nissen S.E., Yeomans N.D., Solomon D.H. et al; PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis // N. Engl. J. Med. — 2016 Dec 29. — 375(26). — 2519-2529.

Patrono C., Baigent C. Coxibs, Traditional NSAIDs, and Cardiovascular Safety PostPRECISION: What We Thought We Knew Then and What We Think We Know Now // Clin. Pharmacol. Ther. — 2017. — 102(2). — 238-245.

Pelletier J.P., Martel-Pelletier J., Rannou F., Cooper C. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys // Semin. Artritis Rheum. — 2016. — 45(4 Suppl.). — S22-27.

Reginster J., Malmstrom K., Mehta A. et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis // Ann. Rheum. Dis. — 2007. — 66(7). — 945-951.

Sieper J., Lenaerts J., Wollenhaupt J. et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 // Ann. Rheum. Dis. — 2014. — 73(1). — 101-107.

Simmons R., Owen S., Abbott C. et al. Naproxen sodium and paracetamol/dextropropoxyphene in sports injuries — a multicentre comparative study // Br. J. Sports Med. — 1982. — 16(2). — 91-95.

Simon L.S., Weaver A.L., Graham D.Y. et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial // JAMA. — 1999. — 282. — 1921-1928.

Singh G., Fort J., Goldstein J., et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study // Am. J. Med. — 2006. — 119(3). — 255-266.

Smith S.R., Deshpsnde B.R., Collins J.E. et al. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review // Osteoarthritis Cartilage. — 2016. — 24(6). — 962-972.

Song G., Seo Y., Kim J. et al. Relative efficacy and tole­rability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis: A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal // J. Rheumatol. — 2016. — 75(5). — 508-516.

Sturge R.A., Scott J.T., Hailton E.B. et al. Multicentre trial of naproxen and phenylbutazone in acute gout // Ann. Rheum. Dis. — 1977. — 36(1). — 80-82.

Trelle S., Reichenbach S., Wandel S. et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis // BMJ. — 2011. — 342. — 7086.

Willkens R.F., Case J.B., Huix F.J. The treatment of acute gout with naproxen // J. Clin. Pharmacol. — 1975. — 15 (4 Pt. 2). — 363-366.




Copyright (c) 2018 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта